Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
about
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaChronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.Role of allo-SCT for CML in 2010.Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
P2860
Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Imatinib use either pre- or po ...... myelogenous leukemia patients.
@en
Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation
@nl
type
label
Imatinib use either pre- or po ...... myelogenous leukemia patients.
@en
Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation
@nl
prefLabel
Imatinib use either pre- or po ...... myelogenous leukemia patients.
@en
Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation
@nl
P2093
P2860
P356
P1476
Imatinib use either pre- or po ...... myelogenous leukemia patients.
@en
P2093
D J Weisdorf
J E Wagner
M R Verneris
P2860
P2888
P304
P356
10.1038/BMT.2008.441
P407
P577
2009-02-09T00:00:00Z
P5875
P6179
1040793503